Clinical Trial

The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 13, 2022 (before its estimated December 31, 2023 completion). Its status may not reflect the trial's current state.
Summary
To observe the efficiency for patient with stage II-III HR+/HER2+ early breast cancer with standard neoadjuvant therapy, a retrospective, multicenter study in real world settings.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-02-27; most recent amendment 2022-09-12.
Status change: Not Yet Recruiting → Recruiting 2022-07-30
Trial Details
NCT Number NCT05263570
Lead Sponsor Shengjing Hospital
Conditions Breast Cancer
Enrollment 200 participants
Start Date 2022-08-01
Primary Completion 2023-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2022-09-13